Hebei Changshan Biochemical Pharmaceutical Co.,Ltd.

On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Hebei Changshan Biochemical Pharmaceutical Co.,Ltd.

24 YRS

Jiangsu, China

CNY 935.0 Million

176490 m²

Over 1000 people

Main Products: Heparin Sodium / Heparin Calcium / Enoxaparin Sodium

Jiangsu, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

VERIFIEDMANUFACTURINGCOMPANY

Business Type

Manufacturer

Total Employees

1000+ People

Plant Size

265 Acres

Total Annual Revenue

CNY 2158 Million

Production Experience

24+ Years

MAIN
PRODUCTS

1/3

Heparin Sodium

CAS: 9041-08-1

Packing: 5 KG/BOTTLE

Lead Time: 14-30 days

Inquiry

1/3

Heparin Calcium

CAS: 37270-89-6

Packing: 5 KG/BOTTLE

Lead Time: 14-30 days

Inquiry

1/3

Nadroparin calcium

CAS: 37270-89-6

Packing: 3 KG/BOTTLE

Lead Time: 14-30 days

Inquiry

ABOUT US

Hebei Changshan Biochemical Pharmaceutical Co.,Ltd.

Founded in 2000, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was listed on the gem of Shenzhen Stock Exchange on August 19, 2011 (Stock Code: 300255). At present, it has a registered capital of 935 million yuan and total assets of 3.5 billion yuan. It has four production bases, nine subsidiaries, two overseas companies and two joint ventures. The company is a biochemical pharmaceutical enterprise integrating R & D, production, sales and import and export trade. In the field of heparin, it is a key high-tech enterprise with a complete heparin industrial chain from crude heparin products to low molecular weight heparin injection products. It is one of the leading enterprises of heparin series drugs in China. Since its establishment, the company has focused on R & D, production and marketing of drugs for cardiovascular and cerebrovascular diseases, diabetes drugs and anticancer drugs, and has actively expanded medical devices, beauty, precision medicine and other fields, and products are exported to many countries in the world. The company pays attention to the development of new drugs and establishes Changshan Pharmaceutical Research Institute, which aims to build a new drug R & D and information sharing center of the company, so as to play the main role of innovation through the collection and analysis of the latest cutting-edge information of new drugs, the selection of key R & D varieties, the integration of various R & D resources and the introduction and training of R & D talents, Serving the company's strategic goal of vigorously developing innovative drugs in the medium and long term is an important measure for the implementation of the company's strategy and is of positive significance to the company's future development. The company invests a lot of money in technological innovation every year, and has made great breakthroughs in innovation and cooperation. In the next 1 to 3 years, low molecular weight heparin water injection preparation will enter the European and American markets, and the company will achieve the "double hundred" goal: enter the top 100 pharmaceutical enterprises in China, with a sales revenue of more than 10 billion yuan, and build Changshan pharmaceutical into a world-class innovative new drug R & D and production enterprise. In order to achieve these goals, we will continue to strengthen R & D investment on the basis of existing product lines and increase innovative product projects with independent intellectual property rights.